<unk>  was withdrawn in 2000 following the association of<unk>  with serious life-threatening gastrointestinal adverse effects. The cumulative incidence of ischaemic colitis was 2 in 1000, while serious complications arising from constipation (obstruction, perforation, impaction, toxic megacolon, secondary colonic ischaemia, death) was 1 in 1000. A 1999 review performed by FDA medical officer John Senior, indicated that 27% of patients experienced constipation. The phase III trial reported constipation occurred in 30% and 3% of patients in the<unk>  and placebo groups, respectively. It was cited as the most important reason for patients dropping out of the study.
Alosetron
Tropisetron
Granisetron
Cilansetron
Palonosetron
Avacopan
Agomelatine
Bocasan